Subscribe free

Newsletter

HPB & Spleen

Every new paper in this field, in your inbox.

FreeNo spamOne-click unsubscribe
Am J Surg18 Mar 2024

Robotic Surgery Shows Promise for Gallbladder Cancer Treatment

Robotic-assisted surgery for gallbladder cancer is found to be as effective as traditional methods in terms of oncological outcomes, with potential benefits in precision and perioperative recovery. A systematic review comparing robotic, open, and laparoscopic techniques highlights the feasibility and safety of robotic surgery, suggesting…

J Gastrointest Surg17 Mar 2024

Higher burden and inequality in pancreatic cancer among older adults globally

Between 1990 and 2019, the number of pancreatic cancer deaths in older adults, age-standardized death rate, disability-adjusted life years, and age-standardized DALY rate increased globally. The burden is highest in southern Latin America and has grown fastest in the Caribbean. Males aged 65 to 74…

Ann Surg16 Mar 2024

Antibiotic Duration Unaffected by Biliary Stents in Pancreatoduodenectomy

Antibiotic duration did not impact infection rates in pancreatoduodenectomy patients with biliary stents. A retrospective cohort study found similar composite infection rates among patients receiving short, medium, or long-duration antibiotics, with no significant differences in other outcomes. Postoperative pancreatic fistula and male sex were associated…

Liver Cancer16 Mar 2024

Enhanced Survival Benefit with Surgical Resection in BCLC-A/B HCC Beyond Milan Criteria

Patients with BCLC-A/B HCC beyond Milan criteria and tumor burden beyond the up-to-7 criteria but within 3 tumors showed better overall survival with surgical resection compared to transarterial chemoembolization. The seven-eleven criteria can help identify candidates for surgical resection in this patient population, emphasizing the…

Ann Surg Oncol15 Mar 2024

Adjuvant Chemoradiation Improves Survival in Resected Biliary Adenocarcinoma

Analyzing a national cancer database, researchers found that adjuvant chemoradiation in resected extrahepatic bile duct or gallbladder adenocarcinoma, following the SWOG S0809 protocol, yielded a median overall survival of 36.9 months. A propensity score-matched cohort revealed a survival benefit for those receiving adjuvant chemoradiation over…